Objective: To observe the effects of double plasma molecular adsorption system(DPMAS) combined with plasma exchangeon cytokines expression and liver function in patients with liver failure. Methods: 60 patients with hepatic failure treated in our hospital from January 2015 to October 2017 were selected, the clinical efficacy, serum cytokines including interleukin(IL)-4, IL-6, tumor necrosis factor α(TNF-α), IL-10 and liver function after treatment were analyzed.Results: After treatment, the symptoms such as fatigue, anorexia, abdominal distension, jaundice and ascites were improved. Among the 60 patients,46 cases were improved after treatment(the improvement roote was 76.67%), 11 cases were discharged automatically and 3 cases died. The changes in liver function indexes[alanine transaminase(ALT), aspartate transaminase(AST), direct bilirubin(DBiL), total bile acid(TBA) and total bilirubin(TBil)] were statistically significant(P<0.05). The changes in serum cytokines(IL-4, IL-6, TNF-α, IL-10) were statistically significant(P<0.05). Adverse reactions occurred in 11 patients,and all were relieved after expectant treatment.Conclusion: DPMAS combined with plasma exchange for liver failure can effectively decrease the levels of pro-inflammatory cytokine in patients. It also improves the liver function and relieves the clinical symptoms, which deserves clinical attention. |
[1] 杨黎冰,仝静,祖晓满,等.血浆置换治疗乙肝相关性肝衰竭的疗效分析[J]. 临床消化病杂志,2017,29(6):342-345.
[2] 徐晖,潘成,何雪明,等.血浆置换对肝衰竭患者血清炎症因子表达的影响[J]. 中外医学研究,2018,16(10):11-13.
[3] PRUSINSKAS B,KATHEMANN S,PILIC D,et al. Cholestasis after pediatric liver transplantation-recurrence of a progressive familial intrahepatic cholestasis phenotype as a rare differential diagnosis:a case report[J]. Transplant Proc,2017,49(7):1628-1633.
[4] 张国民,韩智炜,牛兴杰,等.IL-6、CD14、CD64检测在感染所致肝衰竭患者中意义[J].现代医学,2019,47(2):137-140.
[5] WAN Y M,AUID-OHO,LI Y H,et al. Therapeutic plasma exchange versus double plasma molecular absorption system in hepatitis B virus-infected acute-on-chronic liver failure treated by entercavir:a prospective study[J]. J Clin Apher,2017,32(6):453-461.
[6] 张良杰,陈慧娟,赵守松. 血浆置换对肝衰竭患者细胞因子表达的影响[J]. 临床肝胆病杂志,2015,31(4):578-581.
[7] 林锋.肝衰竭的临床诊断、预后评估和治疗进展[J]. 临床肝胆病杂志,2016,32(9):1678-1683.
[8] KARVELLAS C J,SUBRAMANIAN R M. Current evidence for extracorporeal liver support systems in acute liver failure and acute-on-chronic liver failure[J]. Crit Care Clin,2016,32(3):439-451.
[9] 程芝灵,孙桂香,林辉,等. 血浆置换治疗肝衰竭临床疗效和安全性的Meta分析[J]. 中国循证医学杂志,2015,15(6):664-671.
[10] 龙富立,刘美莲,梁潇月,等. 110例慢性肝衰竭患者的病因构成及预后影响因素分析[J]. 广西医学,2016,38(1):17-19.
[11] 郑晓君,严敬,龚文兰,等. 人工肝不同模式治疗肝衰竭疗效分析[J]. 广东医学,2018,39(5):730-732,736.
[12] 朱立娜,刘峰,唐源,等. 血浆置换联合双重血浆吸附系统治疗急性肝功能衰竭临床观察[J]. 云南医药,2018,39(3):235-237.
[13] JAIN V,DHAWAN A. Extracorporeal lier support systems in paediatric liver failure[J]. J Pediatr Gastroenterol Nutr,2017,64(6):855-863.
[14] 张志恒,李俊生,施晓雷.血红素加氧酶-1对急性肝衰竭大鼠肝组织HMGB1及炎症的影响[J].东南大学学报(医学版),2016,35(2):171-175.
[15] 更藏尖措,汪祖兰,于国英. 双重血浆分子吸附系统治疗慢加急性肝衰竭的临床疗效[J]. 山东医药,2018,58(25):1-4.
[16] 杨梅,刘丽英,陈容,等. 血浆置换联合双重血浆分子吸附系统治疗急性肝衰竭的疗效分析[J]. 中国临床医生杂志,2018,46(7):792-794.
[17] 赵维佳,王选俊. 血浆置换治疗肝衰竭的临床分析[J]. 吉林医学,2014,(27):6057-6058.
[18] KOK B,ELW L,LEE W M,et al. Acute liver failure from tumor necrosis factor-alpha antagonists:report of four cases and literature review[J]. Dig Dis Sci,2018,63(6):1654-1666.
[19] 龚锐,姚云清. 人工肝血浆置换治疗对慢加急性肝衰竭患者血清中促肝细胞生长因子表达的动态研究[J]. 中国社区医师,2016,32(12):7,9.
[20] 周渐,万红.肝衰竭患者血浆置换治疗前后细胞因子的变化与预后的关系[J]. 临床肝胆病杂志,2013,29(7):535-537.
[21] 和鹰.DPMAS联合血浆置换与单纯血浆置换治疗重型肝炎不良反应对比分析[J]. 系统医学,2018,3(9):69-70,73. |